FDA releases quarterly drug-safety list; AZ workers' strike spurs M&A rumors in U.K.;

@FiercePharma: Genzyme set for Cerezyme supply boost. Article | Follow @FiercePharma

> The FDA has released its latest list of possible drug safety concerns, citing Roche's (ROG.VX) breast cancer drug Herceptin and Sanofi-Aventis' (SASY.PA) heart drug Multaq, among others. News

> News of AstraZeneca employees striking has given rise to speculation the drug giant is setting itself up as an M&A target. Report

> French drug maker Servier's heart rate-lowering agent Procoralan cuts the risk of death and hospitalization for heart failure patients by more than a quarter when added to standard therapy, according to new research. Item

> Fitch Ratings lowered its outlook for Bristol-Myers Squibb (BMS) to "Negative" from "Stable" and also affirmed several of the drug maker's debt ratings. Report

> India's Lupin has high hopes for its generic tuberculosis (TB) ethambutol tablet, which has been included by the WHO in the list of pre-qualified medicines. Story

Biotech News

 @FierceBiotech: Roche, Genentech hit with refuse-to-file letter. Article  | Follow @FierceBiotech

> Novartis set to begin late-stage testing of blood thinner. Report

> ImmunoSolv merges to avoid 'one trick pony' syndrome. Item

> Otonomy lands $38.5M for ear disorder work. News

> Eisai heart drug may lower heart risks. Article

Biotech IT News

> Grass-roots effort drives cloud business case. News

> Researchers pit local vs. cloud clusters in compute-intensive race. Item

> Decision tree helps IT discern cloud fit. Report

> Risk approach comes to site monitoring. Story

> Better modeling to reduce animal testing. Article

> EU inspectors tap CDISC in GCP guidance. Item

And Finally... Although immunity to mumps is high in the U.S., mumps vaccine coverage must be maintained and improved to prevent future outbreaks, according to a new study in The Journal of Infectious Diseases. Article

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.